Cboe Proposes Near 24x5 U.S. Equities Trading Amid Regulatory Headwinds

What happened

Cboe Global Markets has filed a proposal with the SEC to launch near 24x5 U.S. equities trading on its EDGX exchange, targeting a December 2026 start pending approvals. This move aims to capitalize on secular trends like global trading hours and could modestly boost the North American Equities segment, which generated $1.5 billion in 2024 revenue. However, the U.S. equities business faces significant regulatory risks, including pending SEC reforms on fee caps and tick sizes that Cboe is contesting in court. Cboe's core growth and profitability remain anchored in high-margin proprietary derivatives like SPX and VIX options, not cash equities. Execution is contingent on regulatory clearance and infrastructure readiness, introducing potential delays or diluted impact.

Implication

Extending U.S. equities trading to near 24x5 could attract incremental volume and enhance Cboe's competitive position in a segment that already contributes significantly to revenue. However, the economics of this business are under severe threat from potential SEC reforms that aim to lower investor costs, which could compress fees and margins despite higher activity. Cboe's pending litigation against these reforms adds a layer of uncertainty; an adverse court decision would materially impact equities profitability and offset any benefits from extended hours. Investors should focus on the durability of SPX/VIX volumes and data revenue from Cboe Data Vantage, which are more critical to the investment thesis due to their high margins and recurring nature. Overall, this initiative is a tactical expansion but does not fundamentally alter the risk-reward profile, emphasizing the need for vigilance on regulatory outcomes and execution risks.

Thesis delta

The proposal reinforces Cboe's strategy to grow its equities footprint but does not shift the core investment thesis, which remains centered on proprietary derivatives and data monetization. Regulatory pressures on U.S. equities economics continue to pose a key downside risk, while the company's strength in SPX/VIX and international expansion supports long-term growth. No material change to the BUY stance is warranted, but investors should monitor the SEC court decision and this initiative's execution closely.